NeuroSense Therapeutics Ltd (NAS:NRSN) Stock News, Headlines & Updates
NeuroSense Therapeutics Ltd Stock News from GuruFocus
- 1
Jun 21, 2024
NeuroSense Receives Delisting Notice from Nasdaq and Intends to Appeal
PRNewswire • 4:00pm
May 20, 2024
NeuroSense Vice President of R&D Shiran Zimri, Ph.D. to Participate in the 3rd Annual ALS Drug Development Summit
PRNewswire • 9:00am
May 14, 2024
NeuroSense Partners with PhaseV to Optimize Upcoming ALS Phase 3 Trial Using Advanced Causal Machine Learning
PRNewswire • 9:00am
May 07, 2024
NeuroSense Announces New Positive Data Analysis from PARADIGM Clinical Trial Demonstrating Statistically Significant Slowing of Disease Progression in High-Risk ALS Patients
PRNewswire • 8:00am
Apr 22, 2024
NeuroSense and Genetika+ Initiate Precision Medicine Collaboration Beginning with Ongoing Phase 2 Clinical Trial in Alzheimer's Disease
PRNewswire • 8:00am
Apr 18, 2024
NeuroSense Presents Positive Data Validating Phase 2b Topline Readout During Emerging Science Presentation at the American Academy of Neurology Annual Meeting
PRNewswire • 8:00am
Apr 12, 2024
NeuroSense to Present PARADIGM Data at the American Academy of Neurology Annual Meeting April 16, 2024
PRNewswire • 8:00am
Apr 11, 2024
NeuroSense Announces Pricing of $4.5 Million Registered Direct Offering and Concurrent Private Placement
PRNewswire • 7:00pm
Apr 09, 2024
- 1
Show
Entries
Headlines
Total 0- 1
No recent news